Ibutamoren
- Generic Name
- Ibutamoren
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N4O5S
- CAS Number
- 159634-47-6
- Unique Ingredient Identifier
- GJ0EGN38UL
Lumos Pharma's Oral LUM-201 Shows Sustained Growth in Pediatric GHD in Phase 2 Trials
• Updated Phase 2 data on LUM-201 demonstrate sustained growth over 24 months in children with moderate Pediatric Growth Hormone Deficiency (PGHD).
• The study showed a significant increase in Annualized Height Velocity (AHV) at six months, which was maintained through 24 months of treatment.
• Data also revealed a correlation between LUM-201's pulsatile mechanism of action and growth, with increases in IGF-1 and IGFBP-3 levels.
• Lumos Pharma plans to advance oral LUM-201 into a Phase 3 clinical trial for moderate PGHD next year.
Lumos Pharma's LUM-201 Shows Promise in Pediatric Growth Hormone Deficiency Trials
• Lumos Pharma's LUM-201 met all primary and secondary endpoints in Phase 2 clinical trials, indicating its potential in treating pediatric growth hormone deficiency.
• The oral growth hormone secretagogue, LUM-201, uniquely stimulates growth hormone release with a pulsatile mechanism, demonstrating durable results up to 24 months.
• Analysts are optimistic about Lumos Pharma's financial stability, with sufficient funds to support operations into Q1 2025 and potential Phase 3 trials.
FDA Approves Dupilumab for Adolescent CRSwNP and Lebrikizumab for Atopic Dermatitis
• Dupilumab (Dupixent) has gained FDA approval as the first drug for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps (CRSwNP), addressing a critical unmet need.
• Lebrikizumab (EBGLYSS) received FDA approval for treating moderate to severe atopic dermatitis in patients 12 and older, offering a new first-line biologic option.
• ACIP recommends that all children and adolescents over 6 months receive at least one updated COVID-19 vaccine booster for the 2024-2025 season, enhancing protection against newer strains.
• Research indicates that metabolic profiles could potentially identify infants at higher risk for sudden infant death syndrome (SIDS), opening avenues for targeted interventions.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath